German Merck to buy Minneapolis Bio-Techne for $11.3B
Germany's Merck KGaA agreed to buy Minneapolis-based Bio-Techne Corp. for about $11.3 billion in cash at $73 a share, the companies said Thursday, June 25, 2026.[1]
Merck is paying $73 per share, about a 36% premium to Bio-Techne's 30-day average.[1] Bio-Techne posted $1.2 billion in sales in 2025 and employs roughly 3,000 people, making it Minnesota's 31st-largest public company.[1] Merck expects about $158 million in cost synergies within three years and plans to fund the deal with cash and debt, targeting closing in late 2026 or early 2027.[1]
Kai Beckmann took office as Merck KGaA's CEO on May 1, 2026, after being named successor in September 2025. The Bio-Techne purchase is Merck's largest deal in more than a decade and its first major move under Beckmann to bulk up the life-sciences unit. The deal also gives Merck a position in New Brighton-based Winter Wolf, a cell-production technology firm that Bio-Techne had backed with a $257 million investment.[1]
An activist investor's recent stake and push for a strategic review preceded the offer, helping to accelerate talks about a sale. The move strengthens Merck's life-sciences footprint as the global life-science tools market was worth about $184 billion in 2025 and Merck's Life Science unit logged €9.0 billion in net sales that year.
The mainstream summary does not mention that this acquisition represents the largest M&A deal involving a Minnesota company in 2026, highlighting its significance within the local context. Additionally, while the summary notes the expected cost synergies of $158 million, it omits the more detailed breakdown provided by social media insights, which indicate that these synergies are projected to reach EUR 140 million annually by year three, suggesting a more robust financial strategy than initially presented.
Furthermore, the summary frames the activist investor's involvement as a mere precursor to the acquisition, but it is essential to recognize that Ananym Capital Management's push for a strategic review was a significant catalyst for the deal. This context underscores the growing influence of activist investors in shaping corporate strategies, particularly in the competitive landscape of life sciences, where companies face urgent pressures from expiring patents and the need for innovation to replenish their pipelines. The global life science tools market's valuation of approximately $184 billion in 2025 further emphasizes the strategic importance of such acquisitions in a rapidly evolving sector.[2][3]
Show source details & analysis (1 source)
📊 Relevant Data
The global life science tools market was valued at approximately $184 billion in 2025.
Life Science Tools Market Size & Share Report, 2026-2033 — Grand View Research
Merck KGaA's Life Science division generated €9.0 billion in net sales in 2025.
Guidance for 2025 Delivered, Growth Foundation in Place — Merck Group
📌 Key Facts
- Merck KGaA will acquire Minneapolis-based Bio-Techne Corp. for approximately $11.3 billion in cash at $73 per share, a 36% premium to the stock’s 30‑day average.
- Bio-Techne reported $1.2 billion in 2025 sales and employs about 3,000 workers, ranking as Minnesota’s 31st largest public company.
- Merck expects about $158 million in cost synergies within three years and plans to fund the deal with cash and debt, targeting closing by late 2026 or early 2027.
- The acquisition gives Merck a stake in New Brighton-based Winter Wolf, a cell-production technology manufacturer that received a $257 million investment from Bio-Techne.
- This is the largest M&A deal involving a Minnesota company since Dayforce’s $12.3 billion sale to Thoma Bravo in August 2025.
📰 Source Timeline (1)
Follow how coverage of this story developed over time